Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca’s Crestor “dramatically reduces” CV risk

AstraZeneca’s Crestor “dramatically reduces” CV risk

10th November 2008

AstraZeneca have announced that Crestor (rosuvastatin calcium) 20 mg has been found to reduce major cardiovascular (CV) events, following research.

The Jupiter (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) study’s results found that patients taking the item saw a drop of 44 per cent, compared to a placebo, among men and women with elevated hsCRP and low to normal cholesterol levels.

Other results from the research found that the risk of heart attack was reduced by over half (54 per cent), with the risk of stroke cut by 48 per cent and total mortality lowered by a fifth (20 per cent).

Chief medical officer for AstraZeneca, Howard Hutchinson, said: “These results provide new information about Crestor’s effects on CV risk.”

He added: “The Jupiter trial confirmed that Crestor dramatically reduces LDL-C cholesterol levels and has now demonstrated a nearly 50 per cent reduction in the risk of heart attack and stroke.”

The study saw a randomised, placebo-controlled, double-blind and long-term study of 17,802 patients, of which the majority had at least one other risk factor including hypertension, low HDL-C, smoking or a family history of premature coronary heart disease.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.